JP2023546536A5 - - Google Patents

Info

Publication number
JP2023546536A5
JP2023546536A5 JP2023547328A JP2023547328A JP2023546536A5 JP 2023546536 A5 JP2023546536 A5 JP 2023546536A5 JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023546536 A5 JP2023546536 A5 JP 2023546536A5
Authority
JP
Japan
Prior art keywords
use according
pharmaceutical composition
dose
fibrosis
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023547328A
Other languages
English (en)
Japanese (ja)
Other versions
JP7868066B2 (ja
JP2023546536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/054713 external-priority patent/WO2022081661A1/en
Publication of JP2023546536A publication Critical patent/JP2023546536A/ja
Publication of JP2023546536A5 publication Critical patent/JP2023546536A5/ja
Priority to JP2026084780A priority Critical patent/JP2026124900A/ja
Application granted granted Critical
Publication of JP7868066B2 publication Critical patent/JP7868066B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023547328A 2020-10-13 2021-10-13 線維症を処置する方法 Active JP7868066B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026084780A JP2026124900A (ja) 2020-10-13 2026-05-20 線維症を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091128P 2020-10-13 2020-10-13
US63/091,128 2020-10-13
PCT/US2021/054713 WO2022081661A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026084780A Division JP2026124900A (ja) 2020-10-13 2026-05-20 線維症を処置する方法

Publications (3)

Publication Number Publication Date
JP2023546536A JP2023546536A (ja) 2023-11-02
JP2023546536A5 true JP2023546536A5 (cg-RX-API-DMAC7.html) 2024-11-14
JP7868066B2 JP7868066B2 (ja) 2026-06-01

Family

ID=81209448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023547328A Active JP7868066B2 (ja) 2020-10-13 2021-10-13 線維症を処置する方法
JP2026084780A Pending JP2026124900A (ja) 2020-10-13 2026-05-20 線維症を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026084780A Pending JP2026124900A (ja) 2020-10-13 2026-05-20 線維症を処置する方法

Country Status (8)

Country Link
US (4) US11628167B2 (cg-RX-API-DMAC7.html)
EP (1) EP4229828A4 (cg-RX-API-DMAC7.html)
JP (2) JP7868066B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230107568A (cg-RX-API-DMAC7.html)
CN (1) CN116349204A (cg-RX-API-DMAC7.html)
AU (1) AU2021360767A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198661A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022081661A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ, インコーポレイテッド 線維症を処置する方法
CN120916760A (zh) * 2023-02-28 2025-11-07 奋进生物医药公司 治疗纤维化的方法
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (cg-RX-API-DMAC7.html) 1977-06-03 1981-03-07 Pfizer
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
GB0013674D0 (en) 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US8536168B2 (en) 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2732101C (en) 2008-08-04 2013-09-17 Amgen Inc. Aurora kinase modulators and methods of use
ES2418479T3 (es) 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2011088404A1 (en) 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
US9970935B2 (en) * 2014-02-06 2018-05-15 The Brigham And Women's Hospital, Inc. Uses of GLI1 in detecting tissue fibrosis
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
EP3383912A4 (en) 2015-11-30 2019-11-06 Ignyta, Inc. TOPICAL FORMULATIONS
US20190255042A1 (en) * 2016-11-04 2019-08-22 Impact Therapeutics, Inc Application of hedgehog pathway inhibitor in treating fibrosis diseases
US11154541B2 (en) 2018-06-29 2021-10-26 The Trustees Of Indiana University Methods for treating aortic valve stenosis with a hedgehog pathway inhibitor
CN112449602A (zh) * 2018-07-19 2021-03-05 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ, インコーポレイテッド 線維症を処置する方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN120916760A (zh) 2023-02-28 2025-11-07 奋进生物医药公司 治疗纤维化的方法

Similar Documents

Publication Publication Date Title
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法(ベムラフェニブ及びmdm2阻害剤)
KR102634247B1 (ko) 다발성 골수종을 치료하기 위한 약물 병용물
KR20140022048A (ko) 선택된 환자에서의 피르페니돈 및 항-섬유성 치료제
JP2019515884A5 (cg-RX-API-DMAC7.html)
JP6091593B2 (ja) 慢性閉塞性肺疾患の急性増悪の治療におけるピラゾール誘導体の使用
EA020193B1 (ru) Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)
JP2004521134A5 (cg-RX-API-DMAC7.html)
EP1358177B1 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
JP6145946B2 (ja) 併用als療法
JP2019520344A5 (cg-RX-API-DMAC7.html)
JP2019533660A5 (cg-RX-API-DMAC7.html)
JP2026510290A (ja) 線維症を処置する方法
JP2022518788A (ja) オピオイド鎮痛耐性を治療するためのmGluR5アンタゴニストの使用
Li et al. A comparative study of esketamine-propofol and sufentanil-propofol for analgesia and sedation during breast minimally invasive rotary resection with local anesthesia: a randomized double-blind clinical trial
JP2023528896A5 (cg-RX-API-DMAC7.html)
JP2013536206A5 (cg-RX-API-DMAC7.html)
JP2019531286A5 (cg-RX-API-DMAC7.html)
JP2020050624A (ja) 線維症治療用医薬組成物
JP2021519285A (ja) ダブラフェニブ、トラメチニブ及びerk阻害剤を含む医薬品の三重の組合せ
JP2009510142A (ja) 急性および慢性肺障害の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用
JP5862897B2 (ja) 腎機能障害の予防又は治療に用いる医薬
CN119837862A (zh) 玛沃谷兰在减少酒精使用或在预防复用酒精中的用途
JP2003513888A (ja) 神経疾患治療用医薬品
JP2024523558A5 (cg-RX-API-DMAC7.html)
US20240207274A1 (en) Larotrectinib and moderate CYP3A4 inducer